Elon Musk’s Neuralink announced Tuesday that 12 people worldwide have received its brain implants, marking steady progress in its clinical rollout.
Key Details
-
Patient Numbers: Up from 7 in June, when partner Barrow Neurological Institute confirmed its involvement.
-
Usage Stats: Collectively, patients have logged 2,000 days of implant use and over 15,000 hours of activity, using the device to control both digital and physical tools through thought.
-
Trials Abroad: A new clinical study will launch in the UK, partnering with University College London Hospitals and Newcastle Hospitals.
-
Funding: Neuralink raised $650 million in June to support expansion.
Background
-
Neuralink began human trials in 2024 after overcoming U.S. FDA safety objections that initially blocked approval in 2022.
-
The company’s implants are aimed at restoring movement and communication for people with severe paralysis, representing a major step in brain-computer interface (BCI) technology.
Outlook
-
The trials will help Neuralink test long-term safety, reliability, and potential new medical applications.
-
If successful, the technology could pave the way for broader use cases — from medical rehabilitation to advanced human-computer interaction.